10-K: Evolus Reports Increased Revenue in 2024, Eyes Evolysse Launch in 2025

Sentiment:

Annual Results 4 March 2025 4:40 PM

Evolus reports a 32% increase in net revenues for 2024, driven by higher sales volumes of Jeuveau, and anticipates launching Evolysse products in 2025.

Summary

Evolus, a global performance beauty company, reported a 32% increase in net revenues for the year ended December 31, 2024, reaching $266.3 million compared to $202.1 million in 2023.
The increase was primarily driven by higher sales volumes of Jeuveau.
The company is preparing for the commercial launch of Evolysse Form and Evolysse Smooth in the United States in the second quarter of 2025, following FDA approval in February 2025.
Evolus also anticipates launching all four approved Evolysse products in Europe in the second half of 2025.
The company incurred a net loss of $50.4 million in 2024, compared to a net loss of $61.7 million in 2023.
As of December 31, 2024, Evolus had cash and cash equivalents of $87.0 million.
The company expects to continue to incur significant expenses as it increases marketing efforts for Jeuveau and prepares for the commercial launch of Evolysse.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive revenue growth offset by continued net losses. The upcoming Evolysse launch provides optimism, but risks remain in a competitive market.

Positives

Significant revenue growth driven by increased sales volume of Jeuveau.
FDA approval of Evolysse Form and Evolysse Smooth, paving the way for U.S. market entry.
Anticipated launch of Evolysse products in Europe, expanding market reach.
Decrease in net loss compared to the previous year.
Successful capital raise through a follow-on offering.

Negatives

The company continues to incur net losses.
The company is reliant on third parties for manufacturing and supply of its products.
The company is subject to ongoing royalty obligations to Medytox, which reduces profitability.

Risks

The company faces significant competition in the medical aesthetics market.
Failure to achieve broad aesthetic practitioner adoption and use or consumer demand could impact commercial success.
The company is dependent on Symatese for regulatory approval and manufacturing of Evolysse.
The company may require additional financing to fund future operations.
Unfavorable global economic conditions could adversely affect the business.

Future Outlook

Evolus anticipates continued sales growth depending on its ability to grow its customer base, increase purchases by current customers, and successfully launch Evolysse products in the United States and Europe.

Industry Context

The medical aesthetics market is highly competitive and dynamic, characterized by rapid technological development and product innovations. Evolus competes with other facial aesthetic products, such as other injectable toxins and dermal fillers, as well as unapproved and off-label treatments.

Comparison to Industry Standards

Evolus competes with major players like AbbVie (BOTOX, Juvderm), Galderma (Dysport, Restylane, Sculptra), and Merz (Xeomin, RADIESSE, Belotero).
The report cites Medical Insights data indicating the global medical aesthetic products market was estimated at $17.1 billion in 2024 and is expected to reach $21.9 billion by 2028.
The facial injectables market, consisting of neurotoxins and hyaluronic acid gels, is estimated to be $10.9 billion in 2024 and is expected to grow to $14.5 billion in 2028.

Legal Proceedings

A securities class action lawsuit against Evolus and certain officers was dismissed.
A shareholder derivative lawsuit is stayed pending the court's decision on the motion to dismiss the Securities Class Action.

Stakeholder Impact

Shareholders may see potential for future growth with the Evolysse launch.
Employees may be impacted by potential cost-cutting measures if the company does not achieve profitability.
Customers will have access to new Evolysse products in the United States and Europe.

Next Steps

Launch Evolysse Form and Evolysse Smooth in the United States in the second quarter of 2025.
Launch all four approved Evolysse products in Europe in the second half of 2025.
Seek PMA approval with the FDA for Evolysse Sculpt and Evolysse Lips.

Key Dates

Date	Description
2013	Evolus entered into a License and Supply Agreement with Daewoong.
2017-12-14	Second Amendment to Stock Purchase Agreement
2018	Jeuveau approved by Health Canada.
2019-02	Jeuveau approved by the U.S. FDA.
2019-05	Commercial launch of Jeuveau in the United States.
2019-09	Jeuveau approved by the European Commission.
2021-02-18	Evolus entered into the Medytox Settlement Agreements.
2022-09-16	End of the Restricted Period under the Medytox Settlement Agreements.
2023-01	Jeuveau approved by the Australian Therapeutics Good Administration.
2023-05-09	Evolus entered into a License, Supply and Distribution Agreement with Symatese.
2023-12-20	Evolus entered into a License, Supply and Distribution Agreement with Symatese for Europe.
2024-10	Regulatory approval received in the European Union for four products in the Evolysse line.
2025-02	FDA approval received for Evolysse Form and Evolysse Smooth in the United States.
2025-Q2	Anticipated launch of Evolysse Form and Evolysse Smooth in the United States.
2025-H2	Anticipated launch of all four approved Evolysse products in Europe.
2026	Expected launch of Evolysse Sculpt in the United States.
2027	Expected launch of Evolysse Lips in the United States.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.